Followers | 9 |
Posts | 1138 |
Boards Moderated | 0 |
Alias Born | 03/20/2022 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, March 20, 2023 5:33:39 AM
As I previously mentioned, either the rvv med team is simply inept at comprehending what the fda requires, or the fda is constantly moving the goal posts re what they require for approval of the ep submission.
I can think of no reasons why rvv would deliberately want to continuously delay the process by providing substandard submissions.
There is no present need for additional trial data, nor do I believe that any data from dr fahy's research at ucsf will have little impact on the ep change request so a desire for delays is simply not there.
I am tending to believe that the fda (among others) is at the root of this obvious farce and that the link below possibly indicates the reason why................
FDA authorizes Pfizer’s Covid omicron booster as fourth shot for kids under 5
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM